Compare GENK & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GENK | HIND |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | 2700 | 18 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 15.2M |
| IPO Year | 2023 | 2016 |
| Metric | GENK | HIND |
|---|---|---|
| Price | $1.95 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.50 | ★ $15.00 |
| AVG Volume (30 Days) | 18.3K | ★ 19.3K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $1.75 |
| 52 Week High | $4.98 | $12.87 |
| Indicator | GENK | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 48.69 |
| Support Level | $1.72 | $1.99 |
| Resistance Level | $2.31 | $2.40 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 8.97 | 22.22 |
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.